Biotech ex­ecs slam Trump’s trav­el ban, count­ing the high cost to a glob­al in­dus­try

A large ma­jor­i­ty of the biotech in­dus­try has ve­he­ment­ly re­ject­ed Don­ald Trump’s trav­el ban in no un­cer­tain terms.

!func­tion(e,t,n,s){var i=”In­fo­gramEm­beds”,o=e.getEle­ments­By­Tag­Name(t),d=o[0],a=/^http:/.test(e.lo­ca­tion)?”http:”:”https:”;if(/^\/{2}/.test(s)&&(s=a+s),win­dow[i]&&win­dow[i].ini­tial­ized)win­dow[i].process&&win­dow[i].process();else if(!e.getEle­ment­ById(n)){var r=e.cre­ateEle­ment(t);r.async=1,r.id=n,r.src=s,d.par­entN­ode.in­sert­Be­fore(r,d)}}(doc­u­ment,”script”,”in­fo­gram-async”,”//e.in­fo­gr.am/js/dist/em­bed-loader-min.js”);

We de­cid­ed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.